Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Senl_H19x22P / SenlangBio
NCT04626765: CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia	Recruiting	1	50	RoW	CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD 19+22, Senl_19+22, Fludarabine, flu, Cyclophosphamide, ctx	Hebei Senlang Biotechnology Inc., Ltd., The Second Hospital of Hebei Medical University	Childhood Acute Lymphoblastic Leukemia	03/23	05/23
NCT04626739: CAR-T Cells in Treating Patients With Relapsed or Refractory NHL	Recruiting	1	100	RoW	CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD19+CD22 CAR-T, Senl_19+22, Fludarabine, flu, Cyclophosphamide, ctx	Hebei Senlang Biotechnology Inc., Ltd.	Refractory Indolent Adult Non-Hodgkin Lymphoma	03/23	03/23
NCT04626726: Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation	Recruiting	1	50	RoW	CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD19+CD22 CAR-T, Senl_19+22, Fludarabine, fiu, Cyclophosphamide, ctx	Hebei Senlang Biotechnology Inc., Ltd.	Adult B Acute Lymphoblastic Leukemia	05/23	05/23
NCT05206071: Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma	Recruiting	N/A	100	RoW	CD19+22 CAR-T cells, CD19+22 CAR-T	Hebei Senlang Biotechnology Inc., Ltd.	Non-hodgkin's Lymphoma	12/23	12/23